Context Therapeutics Inc.
CNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | 0.01 | 0.00 |
| FCF Yield | -47.79% | -116.66% | -135.38% | -120.04% |
| EV / EBITDA | 1.23 | -0.14 | 1.69 | 4.00 |
| Quality | ||||
| ROIC | -31.34% | -211.21% | -44.18% | -21.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.54 | 0.88 | 0.91 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -39.27% | -49.42% | -55.66% | -774.67% |
| Safety | ||||
| Net Debt / EBITDA | 3.53 | 0.58 | 2.39 | 4.72 |
| Interest Coverage | 0.00 | 0.00 | -28.11 | -163.85 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |